Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

• Status: Terminated
• Trial end date: 2018-05-03
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the usefulness of adding Milrinone to the current standard treatment for cerebral vasospasm.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University
• Treatments: Milrinone

Criteria

Inclusion Criteria:

• Subjects ≥ 18 years of age

• Aneurysmal subarachnoid hemorrhage, proven on CT angiogram or digital subtraction angiography

• Aneurysm treated, either by endovascular embolization or surgical clip ligation

• Evidence of increased velocities on transcranial dopplers (TCDs) and/or radiographic evidence of vasospasm as seen on angiogram

• Cerebral vasospasm as demonstrated by patient's clinical exam (new focal deficit or change in mental status not attributable to any other cause)

Exclusion Criteria:

• Recurrent subarachnoid hemorrhage

• Untreated ruptured aneurysm, for any reason

• Patients who die prior to treatment for aneurysm

• Patients who are not able to complete at least 6 months of follow-up

• Patients who are admitted already in vasospasm (i.e. a delayed admission)

• Creatinine clearance less than 20 ml/min

• Women with a positive pregnancy test or who are lactating

• Other comorbidity which may adversely affect patient outcome, at the discretion of the principal investigator